Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aegis Therapeutics
Deal signed to create an anti-obesity nasal spray
June 15th, 2005
Aegis Therapeutics officials and Albany Medical College researchers announced that they have entered into a license agreement relating to the Albany Medical College's patented anti-obesity peptide. Aegis plans to employ its patented Intravail intranasal peptide delivery technology with the Albany Medical College's anti-obesity peptide to assess its commercial potential and to seek appropriate partnerships with pharmaceutical companies interested in the obesity market. "Following the discovery of the hormone leptin and its critical role in curbing appetite by Jeffrey Friedman and his colleagues in 1995, many believed that the ability to treat obesity...
Source: Physician Law Weekly (2005-06-15)
|
